<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00196976</url>
  </required_header>
  <id_info>
    <org_study_id>103533</org_study_id>
    <secondary_id>103534</secondary_id>
    <nct_id>NCT00196976</nct_id>
  </id_info>
  <brief_title>Safety &amp; Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old</brief_title>
  <official_title>Evaluate the Immunogenicity, Reactogenicity, Safety of 4 Different Formulations of GSK Biologicals' Conjugate Vaccine (MenACWY) vs 1 Dose of MenC-CRM197 or Mencevax™ ACWY in Children Aged 12-14 Months &amp; 3-5 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of one
      dose of four different formulations of the MenACWY conjugate vaccine when given to healthy
      children aged 12-14 months and 3-5 years. The selection of the best formulation will be based
      on data obtained up to one month after the vaccine dose.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enrol subjects of 12 to 14 months of age and subjects of 3 to 5 years of age.
      3 formulations of GSK's MenACWY conjugate vaccine will be administered in a double-blind
      manner, while the 4th one will be single-blinded. Administration of the candidate vaccine or
      the active controls (MenC-CRM197 or Mencevax™ ACWY) will be done in an open manner. The study
      will be conducted in two stages: The primary vaccination phase (Study Stage 1) of the study
      will include all subjects; the second (booster/persistence) phase of the study (Study Stage
      2) will include subjects in the active control groups and in the group which was primed with
      the selected MenACWY formulation.

      The study will be conducted in a double-blind manner for groups receiving formulations A, B,
      C and in single blind manner with respect to the group receiving formulation D. The control
      vaccines will be administered in an open manner with respect to the investigational
      vaccination regimens.

      Each group will have one blood sample prior to and one blood sample one month after the first
      vaccine dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 24, 2005</start_date>
  <completion_date type="Actual">March 3, 2006</completion_date>
  <primary_completion_date type="Actual">March 1, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With an Immune Response to Different Meningococcal Serogroups</measure>
    <time_frame>One month after the first vaccine dose (Month 1)</time_frame>
    <description>A responder to serum bactericidal assay meningococcal serogroups A, C, W and Y, using rabbit complement (rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY) was defined as follows: -for initially seronegative subjects (antibody titers &lt; 1:8 for rSBA-Men), a subject achieving a post-vaccination rSBA-Men antibody titer of ≥ 1:32; - for initially seropositive subjects (antibody titers ≥ 1:8 for rSBA-Men), a subject having a ≥ 4-fold increase in rSBA-Men antibody titer from pre to post vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against Different Meningococcal Serogroups</measure>
    <time_frame>Prior to (Month 0) and one month after (Month 1) the first vaccine dose</time_frame>
    <description>A seroprotected subject against meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY assessed, was defined as having antibody titers greater than or equal to (≥) 1:8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for Different Anti-meningococcal Serogroups</measure>
    <time_frame>Prior to (Month 0) and one month after (Month 1) after the first vaccine dose</time_frame>
    <description>A seropositive subject for meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-Y assessed, was defined as having antibody titers greater than or equal to (≥) 1:128.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Titers Against Different Meningococcal Serogroups</measure>
    <time_frame>Prior to (Month 0) and one month after (Month 1) the first vaccine dose</time_frame>
    <description>Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for Different Anti-meningococcal Polysaccharides</measure>
    <time_frame>Prior to (Month 0) and one month after (Month 1) the first vaccine dose</time_frame>
    <description>A seropositive subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the cut-off value of 0.3 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against Different Meningococcal Polysaccharides</measure>
    <time_frame>Prior to (Month 0) and one month after (Month 1) the first vaccine dose</time_frame>
    <description>A seroprotected subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the value of 2.0 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Different Meningococcal Polysaccharides</measure>
    <time_frame>Prior to (Month 0) and one month after (Month 1) the first vaccine dose</time_frame>
    <description>The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for Anti-tetanus (Anti-T)</measure>
    <time_frame>Prior to (Month 0) and one month after (Month 1) the first vaccine dose</time_frame>
    <description>A seropositive subject for anti-tetanus was defined as having antibody concentrations greater than or equal to (≥) the cut-off value of 0.1 international units per milliliter (IU/mL). Antibody titers were determined by enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Tetanus (Anti-T)</measure>
    <time_frame>Prior to (Month 0) and one month after (Month 1) the first vaccine dose</time_frame>
    <description>Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) method, presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Toddlers With Any Solicited Local Symptoms</measure>
    <time_frame>During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose</time_frame>
    <description>The toddlers subgroup received 2 primary vaccine doses, as follows: first dose of a meningococcal vaccine and second dose of a diphtheria, tetanus and acellular pertusis-containing vaccine. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Children With Any Solicited Local Symptoms</measure>
    <time_frame>During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose</time_frame>
    <description>The children subgroup received one dose of the meningococcal vaccine. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Toddlers With Any Solicited General Symptoms</measure>
    <time_frame>During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose</time_frame>
    <description>The toddlers subgroup received 2 primary vaccine doses, as follows: first dose of a meningococcal vaccine and second dose of a diphtheria, tetanus and acellular pertusis-containing vaccine. Assessed solicited general symptoms included drowsiness, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Children With Any Solicited General Symptoms</measure>
    <time_frame>During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose</time_frame>
    <description>The children subgroup received one primary meningococcal vaccine dose. Assessed solicited general symptoms included drowsiness, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against Different Meningococcal Serogroups</measure>
    <time_frame>At one month (M1) and 12 months (M12) post-primary vaccination</time_frame>
    <description>A seroprotected subject against meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY assessed, was defined as having antibody titers greater than or equal to (≥) 1:8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for Different Anti-meningococcal Serogroups</measure>
    <time_frame>At one month (M1) and 12 months (M12) post-primary vaccination</time_frame>
    <description>A seropositive subject for meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-Y assessed, was defined as having antibody titers greater than or equal to (≥) 1:128.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Titers Against Different Meningococcal Serogroups</measure>
    <time_frame>At one month (M1) and 12 months (M12) post-primary vaccination</time_frame>
    <description>Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for Different Anti-meningococcal Polysaccharides</measure>
    <time_frame>At one month (M1) and 12 months (M12) post-primary vaccination</time_frame>
    <description>A seropositive subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the cut-off value of 0.3 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against Different Meningococcal Polysaccharides</measure>
    <time_frame>At one month (M1) and 12 months (M12) post primary vaccination</time_frame>
    <description>A seroprotected subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the value of 2.0 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Different Meningococcal Polysaccharides</measure>
    <time_frame>At one month (M1) and 12 months (M12) post-primary vaccination</time_frame>
    <description>The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive and Seroprotected Subjects Against Different Meningococcal Serogroups</measure>
    <time_frame>Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination</time_frame>
    <description>A seropositive subject for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY was defined as a vaccinated subject with antibody titers greater than or equal to (≥) 1:128, while for a seroprotected subject, titers were ≥1:8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Titers Against Different Meningococcal Serogroups</measure>
    <time_frame>Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination</time_frame>
    <description>Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive and Seroprotected Subjects Against Different Meningococcal Polysaccharides</measure>
    <time_frame>Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination</time_frame>
    <description>A seropositive subject for anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY was defined as a vaccinated subject with antibody concentrations greater than or equal to (≥) 0.3 micrograms per milliliter (μg/mL), while for a seroprotected subject, antibody concentrations were ≥ 2.0 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Different Meningococcal Polysaccharides</measure>
    <time_frame>Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination</time_frame>
    <description>The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Solicited Local Symptoms</measure>
    <time_frame>During the 8-day (Days 0-7) post-vaccination period following booster dose</time_frame>
    <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Solicited General Symptoms</measure>
    <time_frame>During the 8-day (Days 0-7) post-vaccination period following booster dose</time_frame>
    <description>Assessed solicited general symptoms were drowsiness, fever [defined as rectal temperature equal to or above 38.0 degrees Celsius (°C)], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Unsolicited Adverse Events (AEs) After the Primary Vaccination</measure>
    <time_frame>Within 31 days (Days 0-30) after the primary meningococcal vaccination</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Unsolicited AEs During the Primary Vaccination</measure>
    <time_frame>Within 31 days (Days 0-30) post-vaccination with diphteria, tetanus and acellular pertusis-containing vaccine, during the primary vaccination</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Unsolicited AEs</measure>
    <time_frame>Within 31 days (Days 0-30) after the booster vaccination</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>During the primary vaccination study (from Month 0 up to Month 2)</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With SAEs</measure>
    <time_frame>Since the last study contact in the primary study up to the end of the booster study (from Month 2 up to Month 13)</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">461</enrollment>
  <condition>Infections, Meningococcal</condition>
  <arm_group>
    <arm_group_label>GSK134612A Form1 (T), Primary Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK134612A Form2 (T), Primary Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK134612A Form3 (T), Primary Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK134612A Form4 (T), Primary Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (T), Primary Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK134612A Form1 (C), Primary Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK134612A Form2 (C), Primary Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK134612A Form3 (C), Primary Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK134612A Form4 (C), Primary Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (C), Primary Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK134612A Form1 (T), Booster Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (T), Booster Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK134612A Form1 (C), Booster Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (C), Booster Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, did not receive any booster vaccination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Conjugated meningococcal ACWY-TT (vaccine)</intervention_name>
    <description>One intramuscular dose during the primary vaccination</description>
    <arm_group_label>GSK134612A Form1 (T), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form1 (C), Booster Group</arm_group_label>
    <arm_group_label>GSK134612A Form1 (C), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form4 (T), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form3 (T), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form3 (C), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form2 (T), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form4 (C), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form1 (T), Booster Group</arm_group_label>
    <arm_group_label>GSK134612A Form2 (C), Primary Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)</intervention_name>
    <description>One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only</description>
    <arm_group_label>GSK134612A Form1 (T), Primary Group</arm_group_label>
    <arm_group_label>Control (T), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form1 (C), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form4 (T), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form3 (T), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form3 (C), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form2 (T), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form4 (C), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form2 (C), Primary Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)</intervention_name>
    <description>One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only</description>
    <arm_group_label>GSK134612A Form1 (T), Primary Group</arm_group_label>
    <arm_group_label>Control (T), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form1 (C), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form4 (T), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form3 (T), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form3 (C), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form2 (T), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form4 (C), Primary Group</arm_group_label>
    <arm_group_label>GSK134612A Form2 (C), Primary Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningitec™</intervention_name>
    <description>One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age</description>
    <arm_group_label>Control (T), Primary Group</arm_group_label>
    <arm_group_label>Control (T), Booster Group</arm_group_label>
    <arm_group_label>Control (C), Booster Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mencevax™ACWY</intervention_name>
    <description>One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)</description>
    <arm_group_label>GSK134612A Form1 (T), Primary Group</arm_group_label>
    <arm_group_label>Control (T), Primary Group</arm_group_label>
    <arm_group_label>Control (C), Primary Group</arm_group_label>
    <arm_group_label>Control (T), Booster Group</arm_group_label>
    <arm_group_label>GSK134612A Form1 (T), Booster Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Subjects who the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol.

          -  A male or female between, and including 12 and 14 months or 3 and 5 years of age at
             the time of the first vaccination.

          -  Written informed consent obtained from the parent or guardian of the subject.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

          -  Previously completed routine childhood vaccinations to the best of his/her
             parents'/guardians' knowledge. For pertussis vaccination, the children aged 12-14
             months should have been vaccinated with an acellular pertussis vaccine.

        Exclusion criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned
             use during the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the first vaccine dose.

          -  Planned administration/ administration of a vaccine not foreseen by the study protocol
             within one month of the first dose of vaccine and up to one month after administration
             of each study vaccine dose with the exception of oral polio vaccine (OPV).

          -  Previous vaccination against meningococcal serogroup A, C, W-135 or Y disease.

          -  Administration of a H. influenzae type b, diphtheria or tetanus vaccine within 3
             months before the first dose of vaccine.

          -  For subjects aged 12-14 months at enrolment:

               -  For Austria: DTPa-HBV-IPV/Hib booster vaccination in the second year of life:
                  these booster vaccines will be given at Visit 2.

               -  For Greece: DTPa-IPV/Hib booster vaccination in the second year of life: these
                  booster vaccines will be given at Visit 2.

          -  History of meningococcal serogroup A, C, W-135 or Y disease.

          -  Known exposure to meningococcal serogroup A, C, W-135 or Y disease within the previous
             year.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus (HIV) infection.

          -  A family history of congenital or hereditary immunodeficiency.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  Major congenital defects or serious chronic illness.

          -  History of any neurologic disorders or seizures.

          -  Acute disease at the time of enrolment.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first dose of study vaccine or planned administration during the study
             period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>60 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eferding</city>
        <zip>A-4070</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vienna</city>
        <zip>A-1020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Villach</city>
        <zip>A-9500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wels</city>
        <zip>A-4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heraklion, Crete</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ioannina</city>
        <zip>452 21</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Komotini</city>
        <zip>69100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koufalia</city>
        <zip>571 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Markopoulo</city>
        <zip>19003</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>N. Efkarpia, Thessaloniki</city>
        <zip>564 29</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nea Makri</city>
        <zip>19005</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rio/Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tripolis</city>
        <zip>22100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <results_first_submitted>January 11, 2017</results_first_submitted>
  <results_first_submitted_qc>January 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 1, 2017</results_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Meningococcal vaccine</keyword>
  <keyword>Dose selection</keyword>
  <keyword>Toddlers</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Conjugate vaccine</keyword>
  <keyword>Reactogenicity</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Pentetic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>103533</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103533</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103533</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103533</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register. The results of this study 103533 are summarised with study 103534 on the GSK Clinical Study Register.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103533</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103533</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK134612A Form1 (T), Primary Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
        </group>
        <group group_id="P2">
          <title>GSK134612A Form2 (T), Primary Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
        </group>
        <group group_id="P3">
          <title>GSK134612A Form3 (T), Primary Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
        </group>
        <group group_id="P4">
          <title>GSK134612A Form4 (T), Primary Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
        </group>
        <group group_id="P5">
          <title>Control (T), Primary Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
        </group>
        <group group_id="P6">
          <title>GSK134612A Form1 (C), Primary Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
        </group>
        <group group_id="P7">
          <title>GSK134612A Form2 (C), Primary Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
        </group>
        <group group_id="P8">
          <title>GSK134612A Form3 (C), Primary Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
        </group>
        <group group_id="P9">
          <title>GSK134612A Form4 (C), Primary Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
        </group>
        <group group_id="P10">
          <title>Control (C), Primary Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).</description>
        </group>
        <group group_id="P11">
          <title>GSK134612A Form1 (T), Booster Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
        </group>
        <group group_id="P12">
          <title>Control (T), Booster Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
        </group>
        <group group_id="P13">
          <title>GSK134612A Form1 (C), Booster Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.</description>
        </group>
        <group group_id="P14">
          <title>Control (C), Booster Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, did not receive any booster vaccination.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Primary Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="54"/>
                <participants group_id="P7" count="50"/>
                <participants group_id="P8" count="52"/>
                <participants group_id="P9" count="52"/>
                <participants group_id="P10" count="52"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="37"/>
                <participants group_id="P6" count="52"/>
                <participants group_id="P7" count="50"/>
                <participants group_id="P8" count="49"/>
                <participants group_id="P9" count="52"/>
                <participants group_id="P10" count="51"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Migrated from study area</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Booster Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="33"/>
                <participants group_id="P12" count="32"/>
                <participants group_id="P13" count="45"/>
                <participants group_id="P14" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="31"/>
                <participants group_id="P12" count="30"/>
                <participants group_id="P13" count="45"/>
                <participants group_id="P14" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK134612A Form1 (T), Primary Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
        </group>
        <group group_id="B2">
          <title>GSK134612A Form2 (T), Primary Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
        </group>
        <group group_id="B3">
          <title>GSK134612A Form3 (T), Primary Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
        </group>
        <group group_id="B4">
          <title>GSK134612A Form4 (T), Primary Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
        </group>
        <group group_id="B5">
          <title>Control (T), Primary Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
        </group>
        <group group_id="B6">
          <title>GSK134612A Form1 (C), Primary Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
        </group>
        <group group_id="B7">
          <title>GSK134612A Form2 (C), Primary Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
        </group>
        <group group_id="B8">
          <title>GSK134612A Form3 (C), Primary Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
        </group>
        <group group_id="B9">
          <title>GSK134612A Form4 (C), Primary Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
        </group>
        <group group_id="B10">
          <title>Control (C), Primary Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).</description>
        </group>
        <group group_id="B11">
          <title>GSK134612A Form1 (T), Booster Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
        </group>
        <group group_id="B12">
          <title>Control (T), Booster Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
        </group>
        <group group_id="B13">
          <title>GSK134612A Form1 (C), Booster Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.</description>
        </group>
        <group group_id="B14">
          <title>Control (C), Booster Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, did not receive any booster vaccination.</description>
        </group>
        <group group_id="B15">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="41"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="40"/>
            <count group_id="B6" value="54"/>
            <count group_id="B7" value="50"/>
            <count group_id="B8" value="52"/>
            <count group_id="B9" value="52"/>
            <count group_id="B10" value="52"/>
            <count group_id="B11" value="33"/>
            <count group_id="B12" value="32"/>
            <count group_id="B13" value="45"/>
            <count group_id="B14" value="43"/>
            <count group_id="B15" value="614"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Primary study</description>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.5" spread="0.82"/>
                    <measurement group_id="B2" value="12.8" spread="0.86"/>
                    <measurement group_id="B3" value="12.8" spread="0.86"/>
                    <measurement group_id="B4" value="12.9" spread="0.83"/>
                    <measurement group_id="B5" value="12.8" spread="0.79"/>
                    <measurement group_id="B6" value="48.1" spread="7.12"/>
                    <measurement group_id="B7" value="48" spread="7.22"/>
                    <measurement group_id="B8" value="47.8" spread="7.01"/>
                    <measurement group_id="B9" value="48" spread="7.78"/>
                    <measurement group_id="B10" value="47.7" spread="7.15"/>
                    <measurement group_id="B11" value="NA">This group was only included in the Booster study.</measurement>
                    <measurement group_id="B12" value="NA">This group was only included in the Booster study.</measurement>
                    <measurement group_id="B13" value="NA">This group was only included in the Booster study.</measurement>
                    <measurement group_id="B14" value="NA">This group was only included in the Booster study.</measurement>
                    <measurement group_id="B15" value="32.59" spread="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Booster study</description>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B2" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B3" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B4" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B5" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B6" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B7" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B8" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B9" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B10" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B11" value="24.9" spread="1.24"/>
                    <measurement group_id="B12" value="24.9" spread="1.27"/>
                    <measurement group_id="B13" value="60.8" spread="7.23"/>
                    <measurement group_id="B14" value="60.0" spread="7.36"/>
                    <measurement group_id="B15" value="45.32" spread="18.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Primary study</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="23"/>
                    <measurement group_id="B9" value="27"/>
                    <measurement group_id="B10" value="27"/>
                    <measurement group_id="B11" value="NA">This group was only included in the Booster study.</measurement>
                    <measurement group_id="B12" value="NA">This group was only included in the Booster study.</measurement>
                    <measurement group_id="B13" value="NA">This group was only included in the Booster study.</measurement>
                    <measurement group_id="B14" value="NA">This group was only included in the Booster study.</measurement>
                    <measurement group_id="B15" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="33"/>
                    <measurement group_id="B7" value="34"/>
                    <measurement group_id="B8" value="29"/>
                    <measurement group_id="B9" value="25"/>
                    <measurement group_id="B10" value="25"/>
                    <measurement group_id="B11" value="NA">This group was only included in the Booster study.</measurement>
                    <measurement group_id="B12" value="NA">This group was only included in the Booster study.</measurement>
                    <measurement group_id="B13" value="NA">This group was only included in the Booster study.</measurement>
                    <measurement group_id="B14" value="NA">This group was only included in the Booster study.</measurement>
                    <measurement group_id="B15" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Booster study</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B2" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B3" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B4" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B5" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B6" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B7" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B8" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B9" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B10" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B11" value="11"/>
                    <measurement group_id="B12" value="15"/>
                    <measurement group_id="B13" value="16"/>
                    <measurement group_id="B14" value="23"/>
                    <measurement group_id="B15" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B2" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B3" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B4" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B5" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B6" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B7" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B8" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B9" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B10" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B11" value="22"/>
                    <measurement group_id="B12" value="17"/>
                    <measurement group_id="B13" value="29"/>
                    <measurement group_id="B14" value="20"/>
                    <measurement group_id="B15" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Primary study</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White/Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="53"/>
                    <measurement group_id="B7" value="50"/>
                    <measurement group_id="B8" value="50"/>
                    <measurement group_id="B9" value="50"/>
                    <measurement group_id="B10" value="51"/>
                    <measurement group_id="B11" value="NA">This group was only included in the Booster study.</measurement>
                    <measurement group_id="B12" value="NA">This group was only included in the Booster study.</measurement>
                    <measurement group_id="B13" value="NA">This group was only included in the Booster study.</measurement>
                    <measurement group_id="B14" value="NA">This group was only included in the Booster study.</measurement>
                    <measurement group_id="B15" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Booster study</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White/Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B2" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B3" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B4" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B5" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B6" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B7" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B8" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B9" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B10" value="NA">This group was only included in the Primary study.</measurement>
                    <measurement group_id="B11" value="32"/>
                    <measurement group_id="B12" value="31"/>
                    <measurement group_id="B13" value="44"/>
                    <measurement group_id="B14" value="43"/>
                    <measurement group_id="B15" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With an Immune Response to Different Meningococcal Serogroups</title>
        <description>A responder to serum bactericidal assay meningococcal serogroups A, C, W and Y, using rabbit complement (rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY) was defined as follows: -for initially seronegative subjects (antibody titers &lt; 1:8 for rSBA-Men), a subject achieving a post-vaccination rSBA-Men antibody titer of ≥ 1:32; - for initially seropositive subjects (antibody titers ≥ 1:8 for rSBA-Men), a subject having a ≥ 4-fold increase in rSBA-Men antibody titer from pre to post vaccination.</description>
        <time_frame>One month after the first vaccine dose (Month 1)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O2">
            <title>GSK134612A Form2 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form3 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O4">
            <title>GSK134612A Form4 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O5">
            <title>Control (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O6">
            <title>GSK134612A Form1 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O7">
            <title>GSK134612A Form2 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O8">
            <title>GSK134612A Form3 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O9">
            <title>GSK134612A Form4 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O10">
            <title>Control (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an Immune Response to Different Meningococcal Serogroups</title>
          <description>A responder to serum bactericidal assay meningococcal serogroups A, C, W and Y, using rabbit complement (rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY) was defined as follows: -for initially seronegative subjects (antibody titers &lt; 1:8 for rSBA-Men), a subject achieving a post-vaccination rSBA-Men antibody titer of ≥ 1:32; - for initially seropositive subjects (antibody titers ≥ 1:8 for rSBA-Men), a subject having a ≥ 4-fold increase in rSBA-Men antibody titer from pre to post vaccination.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="46"/>
                <count group_id="O9" value="50"/>
                <count group_id="O10" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="45"/>
                    <count group_id="O7" value="45"/>
                    <count group_id="O8" value="44"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="41"/>
                    <measurement group_id="O7" value="38"/>
                    <measurement group_id="O8" value="41"/>
                    <measurement group_id="O9" value="42"/>
                    <measurement group_id="O10" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="45"/>
                    <measurement group_id="O7" value="44"/>
                    <measurement group_id="O8" value="44"/>
                    <measurement group_id="O9" value="46"/>
                    <measurement group_id="O10" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="28"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="48"/>
                    <count group_id="O10" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="46"/>
                    <measurement group_id="O7" value="44"/>
                    <measurement group_id="O8" value="46"/>
                    <measurement group_id="O9" value="48"/>
                    <measurement group_id="O10" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="46"/>
                    <measurement group_id="O7" value="47"/>
                    <measurement group_id="O8" value="45"/>
                    <measurement group_id="O9" value="47"/>
                    <measurement group_id="O10" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against Different Meningococcal Serogroups</title>
        <description>A seroprotected subject against meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY assessed, was defined as having antibody titers greater than or equal to (≥) 1:8.</description>
        <time_frame>Prior to (Month 0) and one month after (Month 1) the first vaccine dose</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O2">
            <title>GSK134612A Form2 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form3 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O4">
            <title>GSK134612A Form4 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O5">
            <title>Control (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O6">
            <title>GSK134612A Form1 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O7">
            <title>GSK134612A Form2 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O8">
            <title>GSK134612A Form3 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O9">
            <title>GSK134612A Form4 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O10">
            <title>Control (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against Different Meningococcal Serogroups</title>
          <description>A seroprotected subject against meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY assessed, was defined as having antibody titers greater than or equal to (≥) 1:8.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="50"/>
                <count group_id="O10" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="46"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="44"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="41"/>
                    <measurement group_id="O7" value="42"/>
                    <measurement group_id="O8" value="40"/>
                    <measurement group_id="O9" value="47"/>
                    <measurement group_id="O10" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="50"/>
                    <measurement group_id="O7" value="47"/>
                    <measurement group_id="O8" value="48"/>
                    <measurement group_id="O9" value="50"/>
                    <measurement group_id="O10" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="47"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="12"/>
                    <measurement group_id="O10" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="47"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="50"/>
                    <measurement group_id="O7" value="47"/>
                    <measurement group_id="O8" value="47"/>
                    <measurement group_id="O9" value="49"/>
                    <measurement group_id="O10" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="48"/>
                    <count group_id="O10" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="34"/>
                    <measurement group_id="O7" value="24"/>
                    <measurement group_id="O8" value="25"/>
                    <measurement group_id="O9" value="36"/>
                    <measurement group_id="O10" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="50"/>
                    <measurement group_id="O7" value="48"/>
                    <measurement group_id="O8" value="48"/>
                    <measurement group_id="O9" value="50"/>
                    <measurement group_id="O10" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="37"/>
                    <measurement group_id="O7" value="42"/>
                    <measurement group_id="O8" value="39"/>
                    <measurement group_id="O9" value="42"/>
                    <measurement group_id="O10" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="51"/>
                    <measurement group_id="O7" value="48"/>
                    <measurement group_id="O8" value="48"/>
                    <measurement group_id="O9" value="50"/>
                    <measurement group_id="O10" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for Different Anti-meningococcal Serogroups</title>
        <description>A seropositive subject for meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-Y assessed, was defined as having antibody titers greater than or equal to (≥) 1:128.</description>
        <time_frame>Prior to (Month 0) and one month after (Month 1) after the first vaccine dose</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O2">
            <title>GSK134612A Form2 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form3 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O4">
            <title>GSK134612A Form4 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O5">
            <title>Control (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O6">
            <title>GSK134612A Form1 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O7">
            <title>GSK134612A Form2 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O8">
            <title>GSK134612A Form3 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O9">
            <title>GSK134612A Form4 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O10">
            <title>Control (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seropositive Subjects for Different Anti-meningococcal Serogroups</title>
          <description>A seropositive subject for meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-Y assessed, was defined as having antibody titers greater than or equal to (≥) 1:128.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="50"/>
                <count group_id="O10" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="46"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="44"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="41"/>
                    <measurement group_id="O7" value="39"/>
                    <measurement group_id="O8" value="40"/>
                    <measurement group_id="O9" value="46"/>
                    <measurement group_id="O10" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="49"/>
                    <measurement group_id="O7" value="47"/>
                    <measurement group_id="O8" value="48"/>
                    <measurement group_id="O9" value="50"/>
                    <measurement group_id="O10" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="47"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="47"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="49"/>
                    <measurement group_id="O7" value="46"/>
                    <measurement group_id="O8" value="45"/>
                    <measurement group_id="O9" value="48"/>
                    <measurement group_id="O10" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="48"/>
                    <count group_id="O10" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="15"/>
                    <measurement group_id="O10" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="50"/>
                    <measurement group_id="O7" value="48"/>
                    <measurement group_id="O8" value="48"/>
                    <measurement group_id="O9" value="49"/>
                    <measurement group_id="O10" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="29"/>
                    <measurement group_id="O7" value="37"/>
                    <measurement group_id="O8" value="32"/>
                    <measurement group_id="O9" value="33"/>
                    <measurement group_id="O10" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="51"/>
                    <measurement group_id="O7" value="48"/>
                    <measurement group_id="O8" value="48"/>
                    <measurement group_id="O9" value="50"/>
                    <measurement group_id="O10" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Titers Against Different Meningococcal Serogroups</title>
        <description>Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).</description>
        <time_frame>Prior to (Month 0) and one month after (Month 1) the first vaccine dose</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O2">
            <title>GSK134612A Form2 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form3 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O4">
            <title>GSK134612A Form4 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O5">
            <title>Control (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O6">
            <title>GSK134612A Form1 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O7">
            <title>GSK134612A Form2 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O8">
            <title>GSK134612A Form3 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O9">
            <title>GSK134612A Form4 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O10">
            <title>Control (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Titers Against Different Meningococcal Serogroups</title>
          <description>Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="50"/>
                <count group_id="O10" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="46"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="44"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" lower_limit="39.3" upper_limit="180.1"/>
                    <measurement group_id="O2" value="77.3" lower_limit="32.9" upper_limit="181.6"/>
                    <measurement group_id="O3" value="68.4" lower_limit="30.1" upper_limit="155.3"/>
                    <measurement group_id="O4" value="76" lower_limit="33.8" upper_limit="170.8"/>
                    <measurement group_id="O5" value="69.1" lower_limit="28.1" upper_limit="169.9"/>
                    <measurement group_id="O6" value="359.7" lower_limit="212" upper_limit="610.4"/>
                    <measurement group_id="O7" value="367.2" lower_limit="222.1" upper_limit="607"/>
                    <measurement group_id="O8" value="375.9" lower_limit="227.4" upper_limit="621.2"/>
                    <measurement group_id="O9" value="465.2" lower_limit="307.2" upper_limit="704.4"/>
                    <measurement group_id="O10" value="427.4" lower_limit="280.3" upper_limit="651.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6648" lower_limit="4787.3" upper_limit="9231.9"/>
                    <measurement group_id="O2" value="5406.8" lower_limit="3961.5" upper_limit="7379.4"/>
                    <measurement group_id="O3" value="6225.2" lower_limit="3510.2" upper_limit="11040.2"/>
                    <measurement group_id="O4" value="3928.6" lower_limit="2851.5" upper_limit="5412.4"/>
                    <measurement group_id="O5" value="125.9" lower_limit="53.1" upper_limit="298.3"/>
                    <measurement group_id="O6" value="7469.5" lower_limit="5468.8" upper_limit="10202.1"/>
                    <measurement group_id="O7" value="7569.7" lower_limit="6044" upper_limit="9480.6"/>
                    <measurement group_id="O8" value="13668.3" lower_limit="11274.3" upper_limit="16570.6"/>
                    <measurement group_id="O9" value="4878" lower_limit="4002.5" upper_limit="5944.9"/>
                    <measurement group_id="O10" value="4556.8" lower_limit="3598" upper_limit="5771.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="47"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="4.1" upper_limit="11.5"/>
                    <measurement group_id="O2" value="4.5" lower_limit="3.8" upper_limit="5.2"/>
                    <measurement group_id="O3" value="4.6" lower_limit="3.8" upper_limit="5.7"/>
                    <measurement group_id="O4" value="6.6" lower_limit="4.2" upper_limit="10.2"/>
                    <measurement group_id="O5" value="5.3" lower_limit="3.8" upper_limit="7.3"/>
                    <measurement group_id="O6" value="12.5" lower_limit="7.6" upper_limit="20.5"/>
                    <measurement group_id="O7" value="7.4" lower_limit="4.7" upper_limit="11.6"/>
                    <measurement group_id="O8" value="11.8" lower_limit="7.5" upper_limit="18.5"/>
                    <measurement group_id="O9" value="8.9" lower_limit="5.7" upper_limit="14.1"/>
                    <measurement group_id="O10" value="11.9" lower_limit="7" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="47"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="656.4" lower_limit="483" upper_limit="892"/>
                    <measurement group_id="O2" value="495.7" lower_limit="334.6" upper_limit="734.4"/>
                    <measurement group_id="O3" value="477.2" lower_limit="245.1" upper_limit="929.4"/>
                    <measurement group_id="O4" value="464.3" lower_limit="324.4" upper_limit="664.5"/>
                    <measurement group_id="O5" value="404.5" lower_limit="222.5" upper_limit="735.4"/>
                    <measurement group_id="O6" value="967.6" lower_limit="672" upper_limit="1393.3"/>
                    <measurement group_id="O7" value="1115" lower_limit="746.4" upper_limit="1665.7"/>
                    <measurement group_id="O8" value="1738.8" lower_limit="1159.7" upper_limit="2607"/>
                    <measurement group_id="O9" value="1197.6" lower_limit="765" upper_limit="1874.7"/>
                    <measurement group_id="O10" value="378.3" lower_limit="257.2" upper_limit="556.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="48"/>
                    <count group_id="O10" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" lower_limit="10.7" upper_limit="36.9"/>
                    <measurement group_id="O2" value="21.1" lower_limit="11.5" upper_limit="38.6"/>
                    <measurement group_id="O3" value="14.5" lower_limit="7.7" upper_limit="27.3"/>
                    <measurement group_id="O4" value="12.1" lower_limit="7.1" upper_limit="20.6"/>
                    <measurement group_id="O5" value="18" lower_limit="9.7" upper_limit="33.6"/>
                    <measurement group_id="O6" value="45.8" lower_limit="27.9" upper_limit="75.2"/>
                    <measurement group_id="O7" value="22.3" lower_limit="12.7" upper_limit="39"/>
                    <measurement group_id="O8" value="23.7" lower_limit="14.2" upper_limit="39.7"/>
                    <measurement group_id="O9" value="44.6" lower_limit="28.1" upper_limit="71"/>
                    <measurement group_id="O10" value="31.5" lower_limit="18" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2781.4" lower_limit="1647" upper_limit="4697.2"/>
                    <measurement group_id="O2" value="3447.5" lower_limit="2484.8" upper_limit="4783.3"/>
                    <measurement group_id="O3" value="2545" lower_limit="1522.2" upper_limit="4254.9"/>
                    <measurement group_id="O4" value="3260.8" lower_limit="2342.1" upper_limit="4539.8"/>
                    <measurement group_id="O5" value="21.7" lower_limit="10.5" upper_limit="44.9"/>
                    <measurement group_id="O6" value="4317.4" lower_limit="3114.8" upper_limit="5984.3"/>
                    <measurement group_id="O7" value="3856.5" lower_limit="3153.4" upper_limit="4716.4"/>
                    <measurement group_id="O8" value="5262.1" lower_limit="4417.8" upper_limit="6267.7"/>
                    <measurement group_id="O9" value="4556.1" lower_limit="3576.6" upper_limit="5803.7"/>
                    <measurement group_id="O10" value="912.7" lower_limit="659.1" upper_limit="1264.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7" lower_limit="27.5" upper_limit="121.3"/>
                    <measurement group_id="O2" value="24.4" lower_limit="12" upper_limit="49.7"/>
                    <measurement group_id="O3" value="32.4" lower_limit="14.3" upper_limit="73"/>
                    <measurement group_id="O4" value="32.9" lower_limit="15.9" upper_limit="68.3"/>
                    <measurement group_id="O5" value="52.8" lower_limit="25.5" upper_limit="109.5"/>
                    <measurement group_id="O6" value="98.7" lower_limit="54.9" upper_limit="177.5"/>
                    <measurement group_id="O7" value="181.9" lower_limit="112.1" upper_limit="295.3"/>
                    <measurement group_id="O8" value="146.8" lower_limit="86.2" upper_limit="250.1"/>
                    <measurement group_id="O9" value="140.6" lower_limit="82.8" upper_limit="238.9"/>
                    <measurement group_id="O10" value="123.6" lower_limit="73.3" upper_limit="208.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2599.9" lower_limit="1531.8" upper_limit="4412.7"/>
                    <measurement group_id="O2" value="2150.9" lower_limit="1486.2" upper_limit="3112.9"/>
                    <measurement group_id="O3" value="1920.9" lower_limit="1014.2" upper_limit="3638.2"/>
                    <measurement group_id="O4" value="3544.7" lower_limit="2480.2" upper_limit="5065.9"/>
                    <measurement group_id="O5" value="75.6" lower_limit="38.1" upper_limit="150.1"/>
                    <measurement group_id="O6" value="5249.1" lower_limit="4107.9" upper_limit="6707.4"/>
                    <measurement group_id="O7" value="5150.5" lower_limit="4149.8" upper_limit="6392.6"/>
                    <measurement group_id="O8" value="5896.3" lower_limit="4686.4" upper_limit="7418.5"/>
                    <measurement group_id="O9" value="7548.4" lower_limit="6116.1" upper_limit="9316.2"/>
                    <measurement group_id="O10" value="1527.3" lower_limit="1110.8" upper_limit="2099.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for Different Anti-meningococcal Polysaccharides</title>
        <description>A seropositive subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the cut-off value of 0.3 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Prior to (Month 0) and one month after (Month 1) the first vaccine dose</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O2">
            <title>GSK134612A Form2 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form3 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O4">
            <title>GSK134612A Form4 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O5">
            <title>Control (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O6">
            <title>GSK134612A Form1 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O7">
            <title>GSK134612A Form2 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O8">
            <title>GSK134612A Form3 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O9">
            <title>GSK134612A Form4 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O10">
            <title>Control (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seropositive Subjects for Different Anti-meningococcal Polysaccharides</title>
          <description>A seropositive subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the cut-off value of 0.3 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="50"/>
                <count group_id="O10" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PSA, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="47"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSA, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="48"/>
                    <measurement group_id="O7" value="45"/>
                    <measurement group_id="O8" value="48"/>
                    <measurement group_id="O9" value="48"/>
                    <measurement group_id="O10" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="47"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="49"/>
                    <measurement group_id="O7" value="45"/>
                    <measurement group_id="O8" value="48"/>
                    <measurement group_id="O9" value="48"/>
                    <measurement group_id="O10" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="48"/>
                    <measurement group_id="O7" value="45"/>
                    <measurement group_id="O8" value="48"/>
                    <measurement group_id="O9" value="48"/>
                    <measurement group_id="O10" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="49"/>
                    <measurement group_id="O7" value="45"/>
                    <measurement group_id="O8" value="46"/>
                    <measurement group_id="O9" value="48"/>
                    <measurement group_id="O10" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against Different Meningococcal Polysaccharides</title>
        <description>A seroprotected subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the value of 2.0 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Prior to (Month 0) and one month after (Month 1) the first vaccine dose</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O2">
            <title>GSK134612A Form2 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form3 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O4">
            <title>GSK134612A Form4 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O5">
            <title>Control (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O6">
            <title>GSK134612A Form1 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O7">
            <title>GSK134612A Form2 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O8">
            <title>GSK134612A Form3 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O9">
            <title>GSK134612A Form4 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O10">
            <title>Control (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against Different Meningococcal Polysaccharides</title>
          <description>A seroprotected subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the value of 2.0 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="50"/>
                <count group_id="O10" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PSA, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="47"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSA, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="48"/>
                    <measurement group_id="O7" value="44"/>
                    <measurement group_id="O8" value="47"/>
                    <measurement group_id="O9" value="34"/>
                    <measurement group_id="O10" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="47"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="44"/>
                    <measurement group_id="O7" value="45"/>
                    <measurement group_id="O8" value="45"/>
                    <measurement group_id="O9" value="47"/>
                    <measurement group_id="O10" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="41"/>
                    <measurement group_id="O7" value="31"/>
                    <measurement group_id="O8" value="41"/>
                    <measurement group_id="O9" value="39"/>
                    <measurement group_id="O10" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="46"/>
                    <measurement group_id="O7" value="40"/>
                    <measurement group_id="O8" value="39"/>
                    <measurement group_id="O9" value="47"/>
                    <measurement group_id="O10" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Different Meningococcal Polysaccharides</title>
        <description>The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).</description>
        <time_frame>Prior to (Month 0) and one month after (Month 1) the first vaccine dose</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O2">
            <title>GSK134612A Form2 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form3 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O4">
            <title>GSK134612A Form4 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O5">
            <title>Control (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O6">
            <title>GSK134612A Form1 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O7">
            <title>GSK134612A Form2 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O8">
            <title>GSK134612A Form3 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O9">
            <title>GSK134612A Form4 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O10">
            <title>Control (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Different Meningococcal Polysaccharides</title>
          <description>The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="50"/>
                <count group_id="O10" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PSA, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="47"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" lower_limit="0.14" upper_limit="0.18"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.14" upper_limit="0.19"/>
                    <measurement group_id="O3" value="0.15" lower_limit="0.15" upper_limit="0.15"/>
                    <measurement group_id="O4" value="0.16" lower_limit="0.14" upper_limit="0.17"/>
                    <measurement group_id="O5" value="0.15" lower_limit="0.15" upper_limit="0.15"/>
                    <measurement group_id="O6" value="0.2" lower_limit="0.17" upper_limit="0.25"/>
                    <measurement group_id="O7" value="0.17" lower_limit="0.15" upper_limit="0.2"/>
                    <measurement group_id="O8" value="0.17" lower_limit="0.15" upper_limit="0.19"/>
                    <measurement group_id="O9" value="0.21" lower_limit="0.17" upper_limit="0.26"/>
                    <measurement group_id="O10" value="0.25" lower_limit="0.18" upper_limit="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSA, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.65" lower_limit="19.83" upper_limit="47.38"/>
                    <measurement group_id="O2" value="22.09" lower_limit="16.35" upper_limit="29.84"/>
                    <measurement group_id="O3" value="34.68" lower_limit="21.7" upper_limit="55.42"/>
                    <measurement group_id="O4" value="4.03" lower_limit="2.72" upper_limit="5.98"/>
                    <measurement group_id="O5" value="0.17" lower_limit="0.14" upper_limit="0.2"/>
                    <measurement group_id="O6" value="20.01" lower_limit="14.53" upper_limit="27.56"/>
                    <measurement group_id="O7" value="12.62" lower_limit="8.74" upper_limit="18.22"/>
                    <measurement group_id="O8" value="24.69" lower_limit="19.14" upper_limit="31.85"/>
                    <measurement group_id="O9" value="3.63" lower_limit="2.62" upper_limit="5.04"/>
                    <measurement group_id="O10" value="13.79" lower_limit="9.04" upper_limit="21.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="47"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" lower_limit="0.14" upper_limit="0.17"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.14" upper_limit="0.17"/>
                    <measurement group_id="O3" value="0.15" lower_limit="0.15" upper_limit="0.15"/>
                    <measurement group_id="O4" value="0.15" lower_limit="0.15" upper_limit="0.16"/>
                    <measurement group_id="O5" value="0.16" lower_limit="0.14" upper_limit="0.17"/>
                    <measurement group_id="O6" value="0.18" lower_limit="0.15" upper_limit="0.22"/>
                    <measurement group_id="O7" value="0.18" lower_limit="0.15" upper_limit="0.23"/>
                    <measurement group_id="O8" value="0.16" lower_limit="0.14" upper_limit="0.17"/>
                    <measurement group_id="O9" value="0.15" lower_limit="0.15" upper_limit="0.16"/>
                    <measurement group_id="O10" value="0.18" lower_limit="0.14" upper_limit="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.67" lower_limit="7.47" upper_limit="15.23"/>
                    <measurement group_id="O2" value="11.23" lower_limit="8.75" upper_limit="14.4"/>
                    <measurement group_id="O3" value="12.91" lower_limit="8.83" upper_limit="18.88"/>
                    <measurement group_id="O4" value="10.74" lower_limit="8.43" upper_limit="13.68"/>
                    <measurement group_id="O5" value="11.99" lower_limit="9.26" upper_limit="15.53"/>
                    <measurement group_id="O6" value="6.33" lower_limit="4.81" upper_limit="8.34"/>
                    <measurement group_id="O7" value="7.76" lower_limit="5.76" upper_limit="10.44"/>
                    <measurement group_id="O8" value="7.71" lower_limit="6.05" upper_limit="9.83"/>
                    <measurement group_id="O9" value="7.78" lower_limit="5.83" upper_limit="10.38"/>
                    <measurement group_id="O10" value="14.44" lower_limit="11.32" upper_limit="18.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.15" upper_limit="0.16"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.15" upper_limit="0.15"/>
                    <measurement group_id="O3" value="0.16" lower_limit="0.14" upper_limit="0.17"/>
                    <measurement group_id="O4" value="0.15" lower_limit="0.15" upper_limit="0.16"/>
                    <measurement group_id="O5" value="0.15" lower_limit="0.15" upper_limit="0.15"/>
                    <measurement group_id="O6" value="0.15" lower_limit="0.15" upper_limit="0.16"/>
                    <measurement group_id="O7" value="0.17" lower_limit="0.15" upper_limit="0.2"/>
                    <measurement group_id="O8" value="0.16" lower_limit="0.15" upper_limit="0.17"/>
                    <measurement group_id="O9" value="0.15" lower_limit="0.15" upper_limit="0.15"/>
                    <measurement group_id="O10" value="0.16" lower_limit="0.14" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.52" lower_limit="4.97" upper_limit="11.36"/>
                    <measurement group_id="O2" value="3.12" lower_limit="2.3" upper_limit="4.22"/>
                    <measurement group_id="O3" value="3.62" lower_limit="2.31" upper_limit="5.68"/>
                    <measurement group_id="O4" value="7.09" lower_limit="5.19" upper_limit="9.7"/>
                    <measurement group_id="O5" value="0.15" lower_limit="0.15" upper_limit="0.15"/>
                    <measurement group_id="O6" value="4.76" lower_limit="3.4" upper_limit="6.66"/>
                    <measurement group_id="O7" value="3.2" lower_limit="2.33" upper_limit="4.39"/>
                    <measurement group_id="O8" value="3.85" lower_limit="2.85" upper_limit="5.21"/>
                    <measurement group_id="O9" value="4.99" lower_limit="3.7" upper_limit="6.73"/>
                    <measurement group_id="O10" value="7.93" lower_limit="5.39" upper_limit="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" lower_limit="0.14" upper_limit="0.18"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.15" upper_limit="0.15"/>
                    <measurement group_id="O3" value="0.16" lower_limit="0.15" upper_limit="0.17"/>
                    <measurement group_id="O4" value="0.16" lower_limit="0.14" upper_limit="0.2"/>
                    <measurement group_id="O5" value="0.15" lower_limit="0.15" upper_limit="0.16"/>
                    <measurement group_id="O6" value="0.16" lower_limit="0.14" upper_limit="0.18"/>
                    <measurement group_id="O7" value="0.19" lower_limit="0.15" upper_limit="0.24"/>
                    <measurement group_id="O8" value="0.16" lower_limit="0.15" upper_limit="0.17"/>
                    <measurement group_id="O9" value="0.15" lower_limit="0.15" upper_limit="0.16"/>
                    <measurement group_id="O10" value="0.15" lower_limit="0.15" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="49"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.86" lower_limit="7.41" upper_limit="15.92"/>
                    <measurement group_id="O2" value="6.71" lower_limit="5.12" upper_limit="8.8"/>
                    <measurement group_id="O3" value="6.01" lower_limit="4" upper_limit="9.03"/>
                    <measurement group_id="O4" value="13.38" lower_limit="9.48" upper_limit="18.89"/>
                    <measurement group_id="O5" value="0.16" lower_limit="0.15" upper_limit="0.17"/>
                    <measurement group_id="O6" value="9.41" lower_limit="6.66" upper_limit="13.31"/>
                    <measurement group_id="O7" value="6.59" lower_limit="4.7" upper_limit="9.25"/>
                    <measurement group_id="O8" value="5.75" lower_limit="4.23" upper_limit="7.81"/>
                    <measurement group_id="O9" value="11.7" lower_limit="8.39" upper_limit="16.32"/>
                    <measurement group_id="O10" value="18.96" lower_limit="13.68" upper_limit="26.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for Anti-tetanus (Anti-T)</title>
        <description>A seropositive subject for anti-tetanus was defined as having antibody concentrations greater than or equal to (≥) the cut-off value of 0.1 international units per milliliter (IU/mL). Antibody titers were determined by enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Prior to (Month 0) and one month after (Month 1) the first vaccine dose</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O2">
            <title>GSK134612A Form2 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form3 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O4">
            <title>GSK134612A Form4 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O5">
            <title>Control (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O6">
            <title>GSK134612A Form1 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O7">
            <title>GSK134612A Form2 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O8">
            <title>GSK134612A Form3 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O9">
            <title>GSK134612A Form4 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O10">
            <title>Control (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seropositive Subjects for Anti-tetanus (Anti-T)</title>
          <description>A seropositive subject for anti-tetanus was defined as having antibody concentrations greater than or equal to (≥) the cut-off value of 0.1 international units per milliliter (IU/mL). Antibody titers were determined by enzyme-linked immunosorbent assay (ELISA).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="50"/>
                <count group_id="O10" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-T, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="49"/>
                    <measurement group_id="O7" value="47"/>
                    <measurement group_id="O8" value="46"/>
                    <measurement group_id="O9" value="48"/>
                    <measurement group_id="O10" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="48"/>
                    <measurement group_id="O7" value="47"/>
                    <measurement group_id="O8" value="48"/>
                    <measurement group_id="O9" value="50"/>
                    <measurement group_id="O10" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Tetanus (Anti-T)</title>
        <description>Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) method, presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL).</description>
        <time_frame>Prior to (Month 0) and one month after (Month 1) the first vaccine dose</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O2">
            <title>GSK134612A Form2 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form3 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O4">
            <title>GSK134612A Form4 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O5">
            <title>Control (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O6">
            <title>GSK134612A Form1 (C), Primary Group</title>
            <description>Healthy male and female childrens (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O7">
            <title>GSK134612A Form2 (C), Primary Group</title>
            <description>Healthy male and female childrens (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O8">
            <title>GSK134612A Form3 (C), Primary Group</title>
            <description>Healthy male and female childrens (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O9">
            <title>GSK134612A Form4 (C), Primary Group</title>
            <description>Healthy male and female childrens (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O10">
            <title>Control (C), Primary Group</title>
            <description>Healthy male and female childrens (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Tetanus (Anti-T)</title>
          <description>Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) method, presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="50"/>
                <count group_id="O10" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-T, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.007" lower_limit="0.671" upper_limit="1.51"/>
                    <measurement group_id="O2" value="1.159" lower_limit="0.814" upper_limit="1.65"/>
                    <measurement group_id="O3" value="1.203" lower_limit="0.871" upper_limit="1.662"/>
                    <measurement group_id="O4" value="1.293" lower_limit="0.826" upper_limit="2.023"/>
                    <measurement group_id="O5" value="0.792" lower_limit="0.578" upper_limit="1.084"/>
                    <measurement group_id="O6" value="1.426" lower_limit="0.94" upper_limit="2.164"/>
                    <measurement group_id="O7" value="1.312" lower_limit="0.935" upper_limit="1.841"/>
                    <measurement group_id="O8" value="1.232" lower_limit="0.849" upper_limit="1.788"/>
                    <measurement group_id="O9" value="1.18" lower_limit="0.823" upper_limit="1.694"/>
                    <measurement group_id="O10" value="1.083" lower_limit="0.742" upper_limit="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="48"/>
                    <count group_id="O9" value="50"/>
                    <count group_id="O10" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.559" lower_limit="5.04" upper_limit="11.335"/>
                    <measurement group_id="O2" value="5.353" lower_limit="3.832" upper_limit="7.477"/>
                    <measurement group_id="O3" value="8.094" lower_limit="4.855" upper_limit="13.492"/>
                    <measurement group_id="O4" value="7.675" lower_limit="4.783" upper_limit="12.315"/>
                    <measurement group_id="O5" value="0.696" lower_limit="0.52" upper_limit="0.932"/>
                    <measurement group_id="O6" value="17.284" lower_limit="11.812" upper_limit="25.292"/>
                    <measurement group_id="O7" value="15.823" lower_limit="11.728" upper_limit="21.348"/>
                    <measurement group_id="O8" value="19.369" lower_limit="13.226" upper_limit="28.363"/>
                    <measurement group_id="O9" value="15.957" lower_limit="11.767" upper_limit="21.639"/>
                    <measurement group_id="O10" value="1.231" lower_limit="0.833" upper_limit="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Toddlers With Any Solicited Local Symptoms</title>
        <description>The toddlers subgroup received 2 primary vaccine doses, as follows: first dose of a meningococcal vaccine and second dose of a diphtheria, tetanus and acellular pertusis-containing vaccine. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.</description>
        <time_frame>During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects who had filled in the symptom sheets.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O2">
            <title>GSK134612A Form2 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form3 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O4">
            <title>GSK134612A Form4 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O5">
            <title>Control (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Toddlers With Any Solicited Local Symptoms</title>
          <description>The toddlers subgroup received 2 primary vaccine doses, as follows: first dose of a meningococcal vaccine and second dose of a diphtheria, tetanus and acellular pertusis-containing vaccine. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects who had filled in the symptom sheets.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Children With Any Solicited Local Symptoms</title>
        <description>The children subgroup received one dose of the meningococcal vaccine. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.</description>
        <time_frame>During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who had filled in the symptom sheets.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O2">
            <title>GSK134612A Form2 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form3 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O4">
            <title>GSK134612A Form4 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O5">
            <title>Control (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Children With Any Solicited Local Symptoms</title>
          <description>The children subgroup received one dose of the meningococcal vaccine. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who had filled in the symptom sheets.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Toddlers With Any Solicited General Symptoms</title>
        <description>The toddlers subgroup received 2 primary vaccine doses, as follows: first dose of a meningococcal vaccine and second dose of a diphtheria, tetanus and acellular pertusis-containing vaccine. Assessed solicited general symptoms included drowsiness, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.</description>
        <time_frame>During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who had filled in the symptom sheets.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O2">
            <title>GSK134612A Form2 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form3 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O4">
            <title>GSK134612A Form4 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O5">
            <title>Control (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Toddlers With Any Solicited General Symptoms</title>
          <description>The toddlers subgroup received 2 primary vaccine doses, as follows: first dose of a meningococcal vaccine and second dose of a diphtheria, tetanus and acellular pertusis-containing vaccine. Assessed solicited general symptoms included drowsiness, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who had filled in the symptom sheets.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Drowsiness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (Axillary), Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (Axillary), Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Children With Any Solicited General Symptoms</title>
        <description>The children subgroup received one primary meningococcal vaccine dose. Assessed solicited general symptoms included drowsiness, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.</description>
        <time_frame>During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who had filled in the symptom sheets.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O2">
            <title>GSK134612A Form2 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form3 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O4">
            <title>GSK134612A Form4 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O5">
            <title>Control (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Children With Any Solicited General Symptoms</title>
          <description>The children subgroup received one primary meningococcal vaccine dose. Assessed solicited general symptoms included drowsiness, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who had filled in the symptom sheets.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (Axillary)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against Different Meningococcal Serogroups</title>
        <description>A seroprotected subject against meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY assessed, was defined as having antibody titers greater than or equal to (≥) 1:8.</description>
        <time_frame>At one month (M1) and 12 months (M12) post-primary vaccination</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for antibody persistence, which included subjects primed with the selected GSK134612A formulation or the control vaccine in both age strata, for whom assay results were available for antibodies against at least one study vaccine antigen component for the Month 12 blood sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O2">
            <title>Control (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form1 (C), Booster Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Control (C), Booster Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, did not receive any booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against Different Meningococcal Serogroups</title>
          <description>A seroprotected subject against meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY assessed, was defined as having antibody titers greater than or equal to (≥) 1:8.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for antibody persistence, which included subjects primed with the selected GSK134612A formulation or the control vaccine in both age strata, for whom assay results were available for antibodies against at least one study vaccine antigen component for the Month 12 blood sampling.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for Different Anti-meningococcal Serogroups</title>
        <description>A seropositive subject for meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-Y assessed, was defined as having antibody titers greater than or equal to (≥) 1:128.</description>
        <time_frame>At one month (M1) and 12 months (M12) post-primary vaccination</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for antibody persistence, which included subjects primed with the selected GSK134612A formulation or the control vaccine in both age strata, for whom assay results were available for antibodies against at least one study vaccine antigen component for the Month 12 blood sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O2">
            <title>Control (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form1 (C), Booster Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Control (C), Booster Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, did not receive any booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seropositive Subjects for Different Anti-meningococcal Serogroups</title>
          <description>A seropositive subject for meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-Y assessed, was defined as having antibody titers greater than or equal to (≥) 1:128.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for antibody persistence, which included subjects primed with the selected GSK134612A formulation or the control vaccine in both age strata, for whom assay results were available for antibodies against at least one study vaccine antigen component for the Month 12 blood sampling.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Titers Against Different Meningococcal Serogroups</title>
        <description>Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).</description>
        <time_frame>At one month (M1) and 12 months (M12) post-primary vaccination</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for antibody persistence, which included subjects primed with the selected GSK134612A formulation or the control vaccine in both age strata, for whom assay results were available for antibodies against at least one study vaccine antigen component for the Month 12 blood sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O2">
            <title>Control (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form1 (C), Booster Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Control (C), Booster Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, did not receive any booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Titers Against Different Meningococcal Serogroups</title>
          <description>Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for antibody persistence, which included subjects primed with the selected GSK134612A formulation or the control vaccine in both age strata, for whom assay results were available for antibodies against at least one study vaccine antigen component for the Month 12 blood sampling.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6577.8" lower_limit="4606.7" upper_limit="9392.4"/>
                    <measurement group_id="O2" value="84.9" lower_limit="32.4" upper_limit="222.8"/>
                    <measurement group_id="O3" value="6565.3" lower_limit="4616.3" upper_limit="9337.2"/>
                    <measurement group_id="O4" value="4649.5" lower_limit="3572.8" upper_limit="6050.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="660.4" lower_limit="484.4" upper_limit="900.3"/>
                    <measurement group_id="O2" value="440.2" lower_limit="227.1" upper_limit="853.1"/>
                    <measurement group_id="O3" value="893.6" lower_limit="600.3" upper_limit="1330.3"/>
                    <measurement group_id="O4" value="416.2" lower_limit="270.5" upper_limit="640.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2523.5" lower_limit="1433.1" upper_limit="4443.7"/>
                    <measurement group_id="O2" value="17.2" lower_limit="7.9" upper_limit="37.8"/>
                    <measurement group_id="O3" value="3893.6" lower_limit="2671.2" upper_limit="5675.6"/>
                    <measurement group_id="O4" value="1004.4" lower_limit="690.4" upper_limit="1461.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2483.9" lower_limit="1363.8" upper_limit="4524.1"/>
                    <measurement group_id="O2" value="57.7" lower_limit="27.1" upper_limit="123.2"/>
                    <measurement group_id="O3" value="4808.5" lower_limit="3653" upper_limit="6329.6"/>
                    <measurement group_id="O4" value="1641.1" lower_limit="1131.2" upper_limit="2380.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2369.1" lower_limit="1642" upper_limit="3418.2"/>
                    <measurement group_id="O2" value="179.3" lower_limit="76.1" upper_limit="422.9"/>
                    <measurement group_id="O3" value="2356.7" lower_limit="1786.7" upper_limit="3108.4"/>
                    <measurement group_id="O4" value="1134.3" lower_limit="767.8" upper_limit="1675.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.2" lower_limit="60.6" upper_limit="200.7"/>
                    <measurement group_id="O2" value="122" lower_limit="59" upper_limit="252.2"/>
                    <measurement group_id="O3" value="172.5" lower_limit="117.7" upper_limit="252.9"/>
                    <measurement group_id="O4" value="41.7" lower_limit="22" upper_limit="79.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="541.8" lower_limit="305.5" upper_limit="961"/>
                    <measurement group_id="O2" value="18.9" lower_limit="8.4" upper_limit="42.9"/>
                    <measurement group_id="O3" value="1322.2" lower_limit="978.3" upper_limit="1786.8"/>
                    <measurement group_id="O4" value="181.7" lower_limit="104.6" upper_limit="315.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="740.3" lower_limit="493.4" upper_limit="1110.9"/>
                    <measurement group_id="O2" value="110.6" lower_limit="51.6" upper_limit="237.1"/>
                    <measurement group_id="O3" value="1400.8" lower_limit="1008.8" upper_limit="1945.1"/>
                    <measurement group_id="O4" value="347.2" lower_limit="228.2" upper_limit="528.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for Different Anti-meningococcal Polysaccharides</title>
        <description>A seropositive subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the cut-off value of 0.3 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>At one month (M1) and 12 months (M12) post-primary vaccination</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for antibody persistence, which included subjects primed with the selected GSK134612A formulation or the control vaccine in both age strata, for whom assay results were available for antibodies against at least one study vaccine antigen component for the Month 12 blood sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O2">
            <title>Control (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form1 (C), Booster Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Control (C), Booster Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, did not receive any booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seropositive Subjects for Different Anti-meningococcal Polysaccharides</title>
          <description>A seropositive subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the cut-off value of 0.3 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for antibody persistence, which included subjects primed with the selected GSK134612A formulation or the control vaccine in both age strata, for whom assay results were available for antibodies against at least one study vaccine antigen component for the Month 12 blood sampling.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PSA, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSA, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against Different Meningococcal Polysaccharides</title>
        <description>A seroprotected subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the value of 2.0 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>At one month (M1) and 12 months (M12) post primary vaccination</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for antibody persistence, which included subjects primed with the selected GSK134612A formulation or the control vaccine in both age strata, for whom assay results were available for antibodies against at least one study vaccine antigen component for the Month 12 blood sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O2">
            <title>Control (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form1 (C), Booster Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Control (C), Booster Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, did not receive any booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against Different Meningococcal Polysaccharides</title>
          <description>A seroprotected subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the value of 2.0 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for antibody persistence, which included subjects primed with the selected GSK134612A formulation or the control vaccine in both age strata, for whom assay results were available for antibodies against at least one study vaccine antigen component for the Month 12 blood sampling.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PSA, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSA, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Different Meningococcal Polysaccharides</title>
        <description>The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).</description>
        <time_frame>At one month (M1) and 12 months (M12) post-primary vaccination</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for antibody persistence, which included subjects primed with the selected GSK134612A formulation or the control vaccine in both age strata, for whom assay results were available for antibodies against at least one study vaccine antigen component for the Month 12 blood sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O2">
            <title>Control (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form1 (C), Booster Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Control (C), Booster Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, did not receive any booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Different Meningococcal Polysaccharides</title>
          <description>The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for antibody persistence, which included subjects primed with the selected GSK134612A formulation or the control vaccine in both age strata, for whom assay results were available for antibodies against at least one study vaccine antigen component for the Month 12 blood sampling.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PSA, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.72" lower_limit="20.12" upper_limit="53.22"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.14" upper_limit="0.2"/>
                    <measurement group_id="O3" value="18.29" lower_limit="12.86" upper_limit="26.01"/>
                    <measurement group_id="O4" value="13" lower_limit="8.19" upper_limit="20.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.25" lower_limit="7.48" upper_limit="16.93"/>
                    <measurement group_id="O2" value="12.43" lower_limit="9.28" upper_limit="16.65"/>
                    <measurement group_id="O3" value="5.64" lower_limit="4.21" upper_limit="7.57"/>
                    <measurement group_id="O4" value="14.5" lower_limit="11.01" upper_limit="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.65" lower_limit="4.29" upper_limit="10.3"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.15" upper_limit="0.15"/>
                    <measurement group_id="O3" value="4.23" lower_limit="2.94" upper_limit="6.09"/>
                    <measurement group_id="O4" value="8.17" lower_limit="5.19" upper_limit="12.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.37" lower_limit="6.74" upper_limit="15.94"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.15" upper_limit="0.17"/>
                    <measurement group_id="O3" value="8.07" lower_limit="5.79" upper_limit="11.24"/>
                    <measurement group_id="O4" value="18.12" lower_limit="12.41" upper_limit="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSA, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="0.68" upper_limit="2.3"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.14" upper_limit="0.21"/>
                    <measurement group_id="O3" value="1.32" lower_limit="0.9" upper_limit="1.95"/>
                    <measurement group_id="O4" value="4.43" lower_limit="2.55" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" lower_limit="0.23" upper_limit="0.66"/>
                    <measurement group_id="O2" value="0.54" lower_limit="0.34" upper_limit="0.86"/>
                    <measurement group_id="O3" value="0.28" lower_limit="0.22" upper_limit="0.36"/>
                    <measurement group_id="O4" value="2.9" lower_limit="1.94" upper_limit="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" lower_limit="1.06" upper_limit="1.74"/>
                    <measurement group_id="O2" value="0.21" lower_limit="0.14" upper_limit="0.32"/>
                    <measurement group_id="O3" value="1.11" lower_limit="0.79" upper_limit="1.57"/>
                    <measurement group_id="O4" value="3.16" lower_limit="1.87" upper_limit="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" lower_limit="1.75" upper_limit="3.18"/>
                    <measurement group_id="O2" value="0.21" lower_limit="0.14" upper_limit="0.33"/>
                    <measurement group_id="O3" value="1.84" lower_limit="1.2" upper_limit="2.82"/>
                    <measurement group_id="O4" value="6.9" lower_limit="4.51" upper_limit="10.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive and Seroprotected Subjects Against Different Meningococcal Serogroups</title>
        <description>A seropositive subject for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY was defined as a vaccinated subject with antibody titers greater than or equal to (≥) 1:128, while for a seroprotected subject, titers were ≥1:8.</description>
        <time_frame>Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for immune memory, which included subjects in the Toddlers subgroup from the ATP cohort for persistence, for whom assay results were available for antibodies against at least one study vaccine antigen component for the post-booster dose blood sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O2">
            <title>Control (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seropositive and Seroprotected Subjects Against Different Meningococcal Serogroups</title>
          <description>A seropositive subject for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY was defined as a vaccinated subject with antibody titers greater than or equal to (≥) 1:128, while for a seroprotected subject, titers were ≥1:8.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for immune memory, which included subjects in the Toddlers subgroup from the ATP cohort for persistence, for whom assay results were available for antibodies against at least one study vaccine antigen component for the post-booster dose blood sampling.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA ≥ 1:8, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC ≥ 1:8, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135 ≥ 1:8, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY ≥ 1:8, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA ≥ 1:128, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC ≥ 1:128, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135 ≥ 1:128, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY ≥ 1:128, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA ≥ 1:8, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC ≥ 1:8, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135 ≥ 1:8, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY ≥ 1:8, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA ≥ 1:128, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC ≥ 1:128, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135 ≥ 1:128, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY ≥ 1:128, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Titers Against Different Meningococcal Serogroups</title>
        <description>Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).</description>
        <time_frame>Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for immune memory, which included subjects in the Toddlers subgroup from the ATP cohort for persistence, for whom assay results were available for antibodies against at least one study vaccine antigen component for the post-booster dose blood sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O2">
            <title>Control (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Titers Against Different Meningococcal Serogroups</title>
          <description>Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for immune memory, which included subjects in the Toddlers subgroup from the ATP cohort for persistence, for whom assay results were available for antibodies against at least one study vaccine antigen component for the post-booster dose blood sampling.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2163.4" lower_limit="1436.6" upper_limit="3257.9"/>
                    <measurement group_id="O2" value="175.7" lower_limit="70.5" upper_limit="437.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.5" lower_limit="50.3" upper_limit="135.4"/>
                    <measurement group_id="O2" value="102.5" lower_limit="47.7" upper_limit="220.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436" lower_limit="243.7" upper_limit="780.2"/>
                    <measurement group_id="O2" value="15.5" lower_limit="7" upper_limit="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="634.5" lower_limit="420" upper_limit="958.3"/>
                    <measurement group_id="O2" value="93.6" lower_limit="38.4" upper_limit="228.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3695.2" lower_limit="1535.2" upper_limit="8894.7"/>
                    <measurement group_id="O2" value="984.6" lower_limit="479.7" upper_limit="2021.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7067.4" lower_limit="4070.7" upper_limit="12270.3"/>
                    <measurement group_id="O2" value="9209.3" lower_limit="5153.4" upper_limit="16457.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5642.4" lower_limit="3360" upper_limit="9475.4"/>
                    <measurement group_id="O2" value="255.6" lower_limit="110.1" upper_limit="593.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3337.7" lower_limit="2013.7" upper_limit="5532.1"/>
                    <measurement group_id="O2" value="323.8" lower_limit="153.6" upper_limit="682.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive and Seroprotected Subjects Against Different Meningococcal Polysaccharides</title>
        <description>A seropositive subject for anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY was defined as a vaccinated subject with antibody concentrations greater than or equal to (≥) 0.3 micrograms per milliliter (μg/mL), while for a seroprotected subject, antibody concentrations were ≥ 2.0 μg/mL.</description>
        <time_frame>Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for immune memory, which included subjects in the Toddlers subgroup from the ATP cohort for persistence, for whom assay results were available for antibodies against at least one study vaccine antigen component for the post-booster dose blood sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O2">
            <title>Control (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seropositive and Seroprotected Subjects Against Different Meningococcal Polysaccharides</title>
          <description>A seropositive subject for anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY was defined as a vaccinated subject with antibody concentrations greater than or equal to (≥) 0.3 micrograms per milliliter (μg/mL), while for a seroprotected subject, antibody concentrations were ≥ 2.0 μg/mL.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for immune memory, which included subjects in the Toddlers subgroup from the ATP cohort for persistence, for whom assay results were available for antibodies against at least one study vaccine antigen component for the post-booster dose blood sampling.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PSA ≥ 0.3 μg/mL, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC ≥ 0.3 μg/mL, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135 ≥ 0.3 μg/mL, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY ≥ 0.3 μg/mL, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSA ≥ 2.0 μg/mL, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC ≥ 2.0 μg/mL, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135 ≥ 2.0 μg/mL, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY ≥ 2.0 μg/mL, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSA ≥ 0.3 μg/mL, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC ≥ 0.3 μg/mL, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135 ≥ 0.3 μg/mL, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY ≥ 0.3 μg/mL, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSA ≥ 2.0 μg/mL, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC ≥ 2.0 μg/mL, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135 ≥ 2.0 μg/mL, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY ≥ 2.0 μg/mL, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Different Meningococcal Polysaccharides</title>
        <description>The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).</description>
        <time_frame>Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for immune memory, which included subjects in the Toddlers subgroup from the ATP cohort for persistence, for whom assay results were available for antibodies against at least one study vaccine antigen component for the post-booster dose blood sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O2">
            <title>Control (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Different Meningococcal Polysaccharides</title>
          <description>The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for immune memory, which included subjects in the Toddlers subgroup from the ATP cohort for persistence, for whom assay results were available for antibodies against at least one study vaccine antigen component for the post-booster dose blood sampling.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PSA, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="0.56" upper_limit="1.69"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.14" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="1.02" upper_limit="1.72"/>
                    <measurement group_id="O2" value="0.19" lower_limit="0.13" upper_limit="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.67" lower_limit="17.39" upper_limit="37.91"/>
                    <measurement group_id="O2" value="3.1" lower_limit="1.34" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY, PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.94" lower_limit="35.87" upper_limit="90.38"/>
                    <measurement group_id="O2" value="1.34" lower_limit="0.63" upper_limit="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSA, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" lower_limit="0.22" upper_limit="0.48"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.31" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" lower_limit="1.69" upper_limit="3.24"/>
                    <measurement group_id="O2" value="0.19" lower_limit="0.13" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.63" lower_limit="7.73" upper_limit="17.5"/>
                    <measurement group_id="O2" value="15.23" lower_limit="10.66" upper_limit="21.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY, Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.03" lower_limit="52.06" upper_limit="119.97"/>
                    <measurement group_id="O2" value="4.19" lower_limit="2" upper_limit="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.</description>
        <time_frame>During the 8-day (Days 0-7) post-vaccination period following booster dose</time_frame>
        <population>The analysis was performed on the Booster Total Vaccinated Cohort, which included all subjects who received the booster dose of Mencevax™ ACWY vaccine and had the symptom sheets filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O2">
            <title>Control (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Solicited Local Symptoms</title>
          <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.</description>
          <population>The analysis was performed on the Booster Total Vaccinated Cohort, which included all subjects who received the booster dose of Mencevax™ ACWY vaccine and had the symptom sheets filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were drowsiness, fever [defined as rectal temperature equal to or above 38.0 degrees Celsius (°C)], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.</description>
        <time_frame>During the 8-day (Days 0-7) post-vaccination period following booster dose</time_frame>
        <population>The analysis was performed on the Booster Total Vaccinated Cohort, which included all subjects who received the booster dose of Mencevax™ ACWY vaccine and had the symptom sheets filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O2">
            <title>Control (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms were drowsiness, fever [defined as rectal temperature equal to or above 38.0 degrees Celsius (°C)], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.</description>
          <population>The analysis was performed on the Booster Total Vaccinated Cohort, which included all subjects who received the booster dose of Mencevax™ ACWY vaccine and had the symptom sheets filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever (Rectally)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Unsolicited Adverse Events (AEs) After the Primary Vaccination</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
        <time_frame>Within 31 days (Days 0-30) after the primary meningococcal vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O2">
            <title>GSK134612A Form2 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form3 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O4">
            <title>GSK134612A Form4 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O5">
            <title>Control (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O6">
            <title>GSK134612A Form1 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O7">
            <title>GSK134612A Form2 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O8">
            <title>GSK134612A Form3 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O9">
            <title>GSK134612A Form4 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O10">
            <title>Control (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Unsolicited Adverse Events (AEs) After the Primary Vaccination</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="52"/>
                <count group_id="O9" value="52"/>
                <count group_id="O10" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Unsolicited AEs During the Primary Vaccination</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
        <time_frame>Within 31 days (Days 0-30) post-vaccination with diphteria, tetanus and acellular pertusis-containing vaccine, during the primary vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O2">
            <title>GSK134612A Form2 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form3 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O4">
            <title>GSK134612A Form4 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O5">
            <title>Control (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Unsolicited AEs During the Primary Vaccination</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Unsolicited AEs</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
        <time_frame>Within 31 days (Days 0-30) after the booster vaccination</time_frame>
        <population>The analysis was performed on the Booster Total Vaccinated Cohort, which included all subjects who received the booster dose of Mencevax™ ACWY vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O2">
            <title>Control (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Unsolicited AEs</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
          <population>The analysis was performed on the Booster Total Vaccinated Cohort, which included all subjects who received the booster dose of Mencevax™ ACWY vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>During the primary vaccination study (from Month 0 up to Month 2)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O2">
            <title>GSK134612A Form2 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form3 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O4">
            <title>GSK134612A Form4 (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O5">
            <title>Control (T), Primary Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
          </group>
          <group group_id="O6">
            <title>GSK134612A Form1 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O7">
            <title>GSK134612A Form2 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O8">
            <title>GSK134612A Form3 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O9">
            <title>GSK134612A Form4 (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
          </group>
          <group group_id="O10">
            <title>Control (C), Primary Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="52"/>
                <count group_id="O9" value="52"/>
                <count group_id="O10" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With SAEs</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>Since the last study contact in the primary study up to the end of the booster study (from Month 2 up to Month 13)</time_frame>
        <population>The analysis was performed on the Booster Total Vaccinated Cohort, which included all subjects who received the booster dose of Mencevax™ ACWY vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK134612A Form1 (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O2">
            <title>Control (T), Booster Group</title>
            <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
          </group>
          <group group_id="O3">
            <title>GSK134612A Form1 (C), Booster Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Control (C), Booster Group</title>
            <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, did not receive any booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With SAEs</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was performed on the Booster Total Vaccinated Cohort, which included all subjects who received the booster dose of Mencevax™ ACWY vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited symptoms: during the 8-day (Days 0-7) post-vaccination period. Unsolicited AEs: within 31 days (Days 0-30) after each vaccination. SAEs: from the beginning of the primary study up to the end of the booster study (from Month 0 up to Month 13).</time_frame>
      <desc>The solicited local and general symptoms were only collected from those subjects who filled in their symptom sheets.</desc>
      <group_list>
        <group group_id="E1">
          <title>GSK134612A Form1 (T), Primary Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
        </group>
        <group group_id="E2">
          <title>GSK134612A Form2 (T), Primary Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
        </group>
        <group group_id="E3">
          <title>GSK134612A Form3 (T), Primary Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
        </group>
        <group group_id="E4">
          <title>GSK134612A Form4 (T), Primary Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
        </group>
        <group group_id="E5">
          <title>Control (T), Primary Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.</description>
        </group>
        <group group_id="E6">
          <title>GSK134612A Form1 (C), Primary Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
        </group>
        <group group_id="E7">
          <title>GSK134612A Form2 (C), Primary Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
        </group>
        <group group_id="E8">
          <title>GSK134612A Form3 (C), Primary Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
        </group>
        <group group_id="E9">
          <title>GSK134612A Form4 (C), Primary Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).</description>
        </group>
        <group group_id="E10">
          <title>Control (C), Primary Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).</description>
        </group>
        <group group_id="E11">
          <title>GSK134612A Form1 (T), Booster Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
        </group>
        <group group_id="E12">
          <title>Control (T), Booster Group</title>
          <description>Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).</description>
        </group>
        <group group_id="E13">
          <title>GSK134612A Form1 (C), Booster Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.</description>
        </group>
        <group group_id="E14">
          <title>Control (C), Booster Group</title>
          <description>Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, did not receive any booster vaccination.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Laryngitis (toddlers subgroup)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Bronchiolitis (toddlers subgroup)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Acute bronchitis (toddlers subgroup)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Maculo-papular rash (toddlers subgroup)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain (GSK134612A conjugate vaccine)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain (Infanrix™-containing vaccine)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Redness (GSK134612A conjugate vaccine)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Redness (Infanrix™-containing vaccine)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Swelling (GSK134612A conjugate vaccine)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Swelling (Infanrix™-containing vaccine)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Drowsiness (GSK134612A conjugate vaccine)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Drowsiness (Infanrix™-containing vaccine)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Axillary/Rectally fever (GSK134612A conjugate vaccine)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Axillary fever (Infanrix™-containing vaccine)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Irritability (GSK134612A conjugate vaccine)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Irritability (Infanrix™-containing vaccine)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Loss of appetite (GSK134612A conjugate vaccine)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Loss of appetite (Infanrix™-containing vaccine)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>None reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

